BioCentury | Nov 14, 2011
Finance

Highlights of weekly biotech stock moves

...Oceana Therapeutics Inc. for $300 million in cash. Salix will gain Oceana's two marketed products: Solesta...
BioCentury | Nov 14, 2011
Company News

Oceana, Salix deal

...Oceana launched Solesta in the U.S. in September. Salix believes peak-year sales for the injectable hyaluronic...
...will acquire Oceana for $300 million in cash. Salix will gain Oceana's two marketed products: Solesta...
BioCentury | Nov 9, 2011
Company News

Salix to acquire Oceana

...Inc. (Edison, N.J.) for $300 million in cash. Salix will gain Oceana's two marketed products: Solesta...
...risk of overt hepatic encephalopathy (HE) recurrence in patients with advanced liver disease. Oceana launched Solesta...
BioCentury | Sep 12, 2011
Company News

Oceana sales and marketing update

...Oceana launched Solesta in the U.S. to treat fecal incontinence. The average wholesale price is $4,428...
...acid biocompatible from Q-Med AB which was acquired by Galderma S.A. (Lausanne, Switzerland) in March. Solesta...
BioCentury | May 30, 2011
Clinical News

Solesta regulatory update

...FDA approved a PMA from Oceana for Solesta to treat fecal incontinence. Oceana previously said it...
...incontinence. Oceana previously said it will conduct a post-approval study to evaluate long-term treatment of Solesta...
...December, an FDA advisory committee voted 5-0, with 1 abstention, that the benefit-risk profile of Solesta...
BioCentury | May 27, 2011
Company News

FDA approves Solesta

...FDA approved a PMA from Oceana Therapeutics Inc. (Edison, N.J.) for Solesta to treat fecal incontinence...
...has exclusive, worldwide rights to the injectable hyaluronic acid biocompatible from Q-Med AB (Uppsala, Sweden). Solesta...
BioCentury | Apr 11, 2011
Clinical News

Solesta regulatory update

...FDA issued an approvable letter for a PMA from Oceana for Solesta to treat fecal incontinence...
...biotech added that it will also conduct a post-approval study to evaluate long-term treatment of Solesta...
...December, an FDA advisory committee voted 5-0, with 1 abstention, that the benefit-risk profile of Solesta...
BioCentury | Apr 8, 2011
Company News

Approvable letter for Oceana's Solesta

...FDA issued an approvable letter for a PMA from Oceana Therapeutics Inc. (Edison, N.J.) for Solesta...
...biotech added that it will also conduct a post-approval study to evaluate long-term treatment of Solesta...
...December, an FDA advisory committee voted 5-0, with 1 abstention, that the benefit-risk profile of Solesta...
BioCentury | Apr 4, 2011
Clinical News

Solesta: Pivotal trial data

...A double-blind, international pivotal trial in 206 patients showed that transanal submucosal injections of Solesta met...
...were eligible to receive open-label Solesta. Data were published in The Lancet. A PMA for Solesta...
...2010). Oceana has exclusive, worldwide rights to Solesta from Q-Med (see BioCentury, April 27, 2009. Solesta...
BioCentury | Dec 6, 2010
Clinical News

Solesta regulatory update

...the Medical Devices Advisory Committee voted 5-0, with 1 abstention, that the benefit-risk profile of Solesta...
...adult patients who have failed conservative therapy. The panel also voted 6-0 and 5-1 that Solesta...
...worldwide rights to the injectable hyaluronic acid biocompatible from Q-Med (see BioCentury, April 27, 2009). Solesta...
Items per page:
1 - 10 of 16